Table 2.
Univariate Cox regression analysis on the matched population.
HR | 95 (%) CI | p value | |
---|---|---|---|
Profiles | |||
Luminal A | 1.00 | ||
Luminal B | 1.55 | 0.84–2.86 | 0.161 |
Luminal HER2 | 1.04 | 0.49–2.19 | 0.921 |
HER2 Positive | 1.28 | 0.57–2.87 | 0.542 |
Triple Negative | 5.67 | 2.81–11.43 | 0.000 |
Age | |||
≥ 45 and ≤ 65 | 1.00 | ||
<45 | 0.81 | 0.51–1.28 | 0.375 |
> 65 | 0.32 | 0.08–1.31 | 0.116 |
Metastatic onset | |||
Relapsed | 1.00 | ||
De novo | 0.84 | 0.59–1.20 | 0.349 |
ECOG PS | |||
0 | 1.00 | ||
1 | 1.70 | 1.15–2.50 | 0.008 |
2 | 1.75 | 1.02–3.01 | 0.043 |
Number of Sites | |||
1 | 1.00 | ||
2 | 1.61 | 1.08–2.40 | 0.019 |
3 | 2.13 | 1.35–3.36 | 0.001 |
Bone only involvement at first line | |||
No | 1.00 | ||
Yes | 0.67 | 0.42–1.06 | 0.084 |
CNS involvement at first line | |||
No | 1.00 | ||
Yes | 2.11 | 1.11–4.04 | 0.023 |
Lung involvement at first line | |||
No | 1.00 | ||
Yes | 1.27 | 0.87–1.85 | 0.211 |
Liver involvement at first line | |||
No | 1.00 | ||
Yes | 1.26 | 0.87–1.83 | 0.214 |
MLR | |||
<0.28 | 1.00 | ||
≥0.28 | 1.77 | 1.24–2.54 | 0.002 |
NLR | |||
<1.95 | 1.00 | ||
≥1.95 | 2.09 | 1.40–3.12 | 0.000 |
PLR | |||
<149.68 | 1.00 | ||
≥149.68 | 1.42 | 1.00–2.03 | 0.051 |
NLR-MLR Score | |||
Score 0 | 1.00 | ||
Score 1 | 2.35 | 1.38–4.02 | 0.002 |
Score 2 | 2.54 | 1.59–4.07 | 0.000 |